Schott predicted that North American demand for RTF manufacturing will increase eight to 10 per cent a year, driven by the growth of key therapeutic markets for diseases like diabetes and cancer.
The firm, which already manufactures vials, ampoules and cartridges at the Lebanon plant, said it will produce up to 270,000 RTF syringes a day when fully operational and added that it will create 40 new jobs over the next 12 months.
Schott plans to begin round-the-clock production in the next two years and added that a further $30m will be invested to boost manufacturing capacity at the site.
The firm, which claims the expansion makes it only the second company to make RTF syringes in the US, did not respond to in-PharmaTechnologist’s request for additional information.